Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roquefort Investments PLC ( (GB:ROQ) ) has issued an announcement.
Roquefort Therapeutics PLC has announced the issuance of 2,466,547 new ordinary shares to settle amounts owed to a former employee. These shares will be admitted to trading on the London Stock Exchange’s Main Market, increasing the company’s total issued share capital to 157,444,030 ordinary shares. This move reflects the company’s ongoing financial management and strategic positioning in the biotech industry, potentially impacting shareholder calculations under the FCA’s Disclosure and Transparency Rules.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the London Stock Exchange, focusing on developing first-in-class medicines in the high-value and high-growth immunology and oncology markets. The company’s portfolio includes five novel, patent-protected pre-clinical anti-cancer and immunology assets.
Average Trading Volume: 1,740,886
Technical Sentiment Signal: Sell
Current Market Cap: £2.79M
For detailed information about ROQ stock, go to TipRanks’ Stock Analysis page.